- $317.77bn
- $361.24bn
- $65.01bn
Merck jumps as lab demand lifts 2026 outlook
Brief: Merck Highlights New Long-Term Data And Advancements Across Broad Oncology Portfolio And Pipeline Research At Asco 2026
Erasca rises after Merck cancer drug combo pact
Human rights lawyer fights megaverdict in Drummond lawsuit
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Big Pharma M&A set for mega year as patent expiries drive deal urgency
U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
US STOCKS-S&P 500, Nasdaq on course for best month since 2020 despite Middle East risks
U.S. STOCKS ON THE MOVE-Qualcomm, Meta, Cardinal Health
US STOCKS-S&P 500, Nasdaq on course for best month since 2020 despite Middle East risks
U.S. STOCKS ON THE MOVE-Royal Caribbean, Labcorp, Textron
US STOCKS-Wall St set to climb at open as earnings optimism overshadows oil woes
U.S. STOCKS ON THE MOVE-Caterpillar, Merck, Qualcomm
US STOCKS-Wall St futures climb as investors balance earnings optimism against oil woes
Merck rises after smaller-than-expected quarterly loss
Merck's Q1 adjusted loss less than expected despite Cidara acquisition charge
Merck posts quarterly loss due to Cidara charge, sales rise 5% (updated)
Brief: Merck Q1 Adjusted Loss Per Share $1.28 Versus IBES Estimate $-1.51
Merck posts quarterly loss due to Cidara charge, sales rise 5%